NCT00297765View on ClinicalTrials.gov

Optimizing Prograf® Therapy in Renal Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

March 31, 2006

Conditions
Renal Transplantation
Interventions
DRUG

Tacrolimus, Prograf®

Trial Locations (42)

10016

New York

10021

New York

10032

New York

11501

Mineola

11794

Long Island City

14203

Buffalo

17033

Hershey

19102

Philadelphia

19104

Philadelphia

19107

Philadelphia

19141

Philadelphia

20037

Washington D.C.

23298

Richmond

27834

Greenville

29425

Charleston

30309

Atlanta

30912

Augusta

35294

Birmingham

37232

Nashville

46202

Indianapolis

48109

Ann Arbor

55455

Minneapolis

61603

Peoria

68198

Omaha

71103

Shreveport

72205

Little Rock

75204

Dallas

77555

Galveston

78284

San Antonio

80262

Denver

84132

Salt Lake City

90057

Los Angeles

92123

San Diego

94115

San Francisco

94304

Palo Alto

96817

Honolulu

98104

Seattle

99208

Spokane

04102

Portland

02114

Boston

07039

Livingston

07052

West Orange

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00297765 - Optimizing Prograf® Therapy in Renal Transplant Patients | Biotech Hunter | Biotech Hunter